Author + information
- Anna Frey, MD∗ (, )
- Stefan Störk, MD and
- Guido Stoll, MD
- ↵∗University Hospital of Würzburg, Comprehensive Heart Failure Center Würzburg, Medical Clinic and Policlinic I, Oberdürrbacher Strasse 6-8, 97080 Würzburg, Germany
In our Cognition Matters HF study (1), we recruited patients between August 2011 and May 2014; thus, it was before sacubitril/valsartan had been approved for clinical use in Europe in 2015 (2). Therefore, our baseline data provided in this paper are not influenced by sacubitril/valsartan intake. This new substance class might become important as a potential confounding factor in the follow-up evaluation. As we thoroughly recorded medication during the conduct of the Cognition Matters HF study, we will be able to adjust our upcoming 3-year long-term results regarding cognitive deficits and morphological brain changes for the intake of sacubitril/valsartan.
Please note: Dr. Störk has served in the German Ministry for Education and Research. All other authors have reported that they have no relationships relevant to the contents of this paper this paper to disclose.
- 2018 American College of Cardiology Foundation
- Frey A.,
- Sell R.,
- Homola G.A.,
- et al.
- ↵European Medicines Agency. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004062/human_med_001929.jsp&mid=WC0b01ac058001d124. Accessed July 3, 2018.